交易 Shionogi & Co., Ltd. - 4507 差价合约

交易条件

• 类型该金融市场可进行差价合约交易。了解更多:差价合约: 差价合约
• 点差: 5.7
• 长仓隔夜仓息调整长仓隔夜仓息调整保证金。您的投资¥1,000隔夜仓息来自头寸全值的费用-0.014438 %(-¥3)使用杠杆的交易规模（大约值）¥20,000来自杠杆的资金 - 美元（大约值）¥19,000前往平台: -0.01444%
• 短仓隔夜仓息调整短仓隔夜仓息调整保证金。您的投资¥1,000隔夜仓息来自头寸全值的费用-0.007784 %(-¥2)使用杠杆的交易规模（大约值）¥20,000来自杠杆的资金 - 美元（大约值）¥19,000前往平台: -0.00778%
• 隔夜调整仓息时间: 21:00 (UTC)
• 货币: JPY
• 最低成交量: 1
• 保证金: 5.00%
• 证券交易所: Japan
• 交易佣金: 0%
• 保证止损溢价保证止损 (GSL) 费用仅在 GSL 被触发时收取。更多详情请参阅我们网站的“服务费用”页面。: 1%

• 保证金。您的投资: ¥1,000
• 隔夜仓息来自头寸全值的费用: -0.014438 %
  (-¥3)

• 保证金。您的投资: ¥1,000
• 隔夜仓息来自头寸全值的费用: -0.007784 %
  (-¥2)

主要统计数据

• 前收盘价: 2861.9
• 开仓: 2801.2
• 1 年变化: -58.96%
• 日区间: 2764.2 - 2805.6

交易 Shionogi & Co., Ltd. - 4507

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company primarily focuses on metabolic syndrome, pain, infectious diseases, cholesterol medication, anti-hypertension drugs, depression treatment, prescription drugs, OTC drugs, and diagnostics. Its primary products include Cymbalta, a serotonin and noradrenaline reuptake inhibitor used for the treatment of depression, anxiety, diabetic neuropathic pain, fibromyalgia pain, chronic lower back pain, and osteoarthritis pain; Intuniv, a selective a2 adrenergic receptor agonist to treat attention-deficit hyperactivity disorder; Xofluza, an anti-influenza agent; and Symproic, a cancer pain analgesic tablet. It has a research collaborative agreement with National University Corporation Kyoto University to focus on drug discovery and medical research for the treatment of psychiatric disorders; strategic collaboration with Sage Therapeutics, Inc. to develop and commercialize SAGE-217 for MDD and other indications; license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics Inc.; a strategic collaboration with Tetra Discovery Partners LLC for the clinical development and commercialization of BPN14770, a selective phosphodiesterase-4D allosteric inhibitor; a collaborative research agreement with PeptiDream Inc. for the discovery and development of a series of blood brain barrier penetrating peptide drug-conjugate; and strategic alliance with Tetra Therapeutics to develop and commercialize BPN14770 for the treatment of Alzheimer's disease, Fragile X syndrome, and other indications. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.